-
-
-
-
-
-
-
Barclays Downgrades Sarepta Therapeutics (SRPT) to Underweight
-
-
-
-
-
-
-
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
-
-
-
-
-
-
Barclays Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)
-
-
-
-
-
-
-
Barclays Downgrades BioCryst Pharma (BCRX) to Equalweight
-
-
-
-
-
-
-
uniQure to Participate in Multiple Upcoming Industry Conferences in September
-
-
-
-
-
-
-
Barclays Starts Orchard Therapeutics (ORTX) at Overweight
-
-
-
-
-
-
-
Spark Therapeutics (ONCE) PT Lowered to $74 at Barclays
-
145 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

